TM-38837
TM-38837 is a small molecule inverse agonist/antagonist of the Cannabinoid [receptor type 1|CB1 cannabinoid receptor], with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials.
TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference but is now known from a more recent reference.